{"filings":[{"id":704356,"accession_number":"0001213900-26-061701","cik":1681682,"company_name":"ENDRA Life Sciences Inc.","ticker":"NDRA","form_type":"8-K","filed_at":"2026-05-28T10:07:05+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"ENDRA raises $3.8M via private placement; believes it regains Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$3.8M from sale of 578,387 shares (or prefunded warrants) and 1,156,774 warrants at $6.57 per unit.","Side letter restricts cash use until strategic alternative closes or payment obligation met; grants board observer right.","Nasdaq notified company of non-compliance on Apr 20, 2026; after offering, company believes equity exceeds $2.5M minimum.","Offering expected to close May 28, 2026; placement agent Lucid Capital Markets.","Proceeds for working capital and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7112431.492537313,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94663,"accession_number":"0001213900-26-045885","cik":1681682,"company_name":"ENDRA Life Sciences Inc.","ticker":"NDRA","form_type":"8-K","filed_at":"2026-04-21T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"ENDRA receives Nasdaq delisting notice for equity falling below $2.5M minimum","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified ENDRA on Apr 20, 2026 that stockholders' equity of $2,260,120 as of Dec 31, 2025 fails the $2.5M minimum.","Company intends to timely request a hearing before Nasdaq Hearings Panel to stay delisting.","ENDRA previously regained compliance in Nov 2025 but is now non-compliant again after annual report filing.","No assurance that the company will regain compliance or succeed in appeal; delisting remains possible."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":7112431.492537313,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107195,"accession_number":"0001213900-26-037497","cik":1681682,"company_name":"ENDRA Life Sciences Inc.","ticker":"NDRA","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ENDRA Life Sciences reports FY2025 net loss $7.0M; initiates strategic alternatives review","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss for Q4 2025 $3.2M vs $4.2M YoY; full year net loss $7.0M vs $11.5M in 2024.","Operating expenses fell to $5.8M in 2025 from $10.8M in 2024.","Cash and cash equivalents $762k as of Dec 31, 2025; $2.0M in digital asset treasury.","Board initiated evaluation of strategic alternatives on March 25, 2026; no timetable set.","TAEUS Liver feasibility study showed r=0.89 correlation with MRI-PDFF for liver fat."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":7112431.492537313,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107194,"accession_number":"0001213900-26-033878","cik":1681682,"company_name":"ENDRA Life Sciences Inc.","ticker":"NDRA","form_type":"8-K","filed_at":"2026-03-25T23:59:59+00:00","items":["2.05","7.01","9.01"],"status":"ready","headline":"ENDRA Life Sciences cuts staff, initiates strategic alternatives review; severance costs $51K","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reduced headcount on March 19, 2026; expects ~$51K in severance charges in Q1 2026.","Board initiated review of strategic alternatives including mergers, asset sales, or sale of company.","Engaged Lucid Capital Management as financial advisor and K&L Gates as legal counsel.","No timetable set for process; will continue executing TAEUS business priorities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7112431.492537313,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123534,"accession_number":"0001213900-25-121374","cik":1681682,"company_name":"ENDRA Life Sciences Inc.","ticker":"NDRA","form_type":"8-K","filed_at":"2025-12-15T23:59:59+00:00","items":["5.02","5.03","5.07","9.01"],"status":"ready","headline":"ENDRA Life Sciences authorized shares increased from 20M to 1B; officer exculpation rejected","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized common shares increased from 20M to 1B via Certificate of Amendment effective Dec 10, 2025.","Stockholders rejected officer exculpation amendment (358,746 for, 63,603 against, 3,587 abstain).","Second Amendment to 2016 Omnibus Incentive Plan approved (406,837 for, 15,223 against).","Four director nominees elected with >418K votes each; RBSM LLP ratified as auditor (680,031 for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7112431.492537313,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123533,"accession_number":"0001213900-25-116103","cik":1681682,"company_name":"ENDRA Life Sciences Inc.","ticker":"NDRA","form_type":"8-K","filed_at":"2025-11-28T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"ENDRA Life Sciences CTO Resigns, Enters Consulting Agreement; CFO Services Formalized","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael Thornton resigned as CTO effective Nov 28, 2025; entered Consulting Agreement at $150/hr (first 5 hrs/week) then $100/hr.","Richard Jacroux continues as CFO via Impact Solve LLC; initial monthly fee $8,650 increasing to $10,800 from Jan 1, 2026.","Thornton's outstanding Options and RSUs remain outstanding and continue to vest during the consulting term.","Impact Solve Advisory Services Agreement replaces prior services agreement for CFO duties."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7112431.492537313,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123532,"accession_number":"0001213900-25-110897","cik":1681682,"company_name":"ENDRA Life Sciences Inc.","ticker":"NDRA","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"ENDRA regains Nasdaq equity compliance after $4.9M offering; adds crypto treasury","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Closed Oct 2025 private placement raising ~$4.9M gross via 744,340 shares and warrants.","Purchased 78,863.1 HYPE tokens on Oct 23, 2025 under new digital asset treasury strategy.","Entered ATM sales agreement with Lucid Capital Markets for up to $1.75M in common stock.","Nasdaq granted extension to Nov 24, 2025; company now believes it meets $2.5M equity minimum."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7112431.492537313,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123531,"accession_number":"0001213900-25-103707","cik":1681682,"company_name":"ENDRA Life Sciences Inc.","ticker":"NDRA","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"ENDRA Life Sciences enters ATM equity facility for up to $1.75M through Lucid Capital Markets","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Aggregate gross proceeds up to $1,750,000 from sale of common stock at-the-market.","Lucid Capital Markets acts as sales agent with a 3.0% commission on gross proceeds.","Sales may be made directly on Nasdaq Capital Market or in negotiated transactions.","Agreement effective October 29, 2025; terminates upon full sale, earlier termination, or 3-year anniversary.","Company has no obligation to sell any shares and may suspend or terminate at any time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":7112431.492537313,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123530,"accession_number":"0001654954-25-012084","cik":1681682,"company_name":"ENDRA Life Sciences Inc.","ticker":"NDRA","form_type":"8-K","filed_at":"2025-10-23T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"ENDRA closes $4.9M PIPE, buys $3M in HYPE tokens, launches crypto treasury strategy","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $4.9M from PIPE; potential additional $9.5M from warrant exercises.","Purchased 78,863.1 HYPE tokens valued at ~$3M as of October 21, 2025 to start digital asset treasury.","Engaged Arca Investment Management as asset manager; Jeff Dorman appointed to Digital Asset Advisory Board.","Custody of digital assets with Anchorage Digital Bank under a Master Custody Service Agreement.","Risk factors highlight potential classification as an investment company under the 1940 Act."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":7112431.492537313,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123529,"accession_number":"0001654954-25-011797","cik":1681682,"company_name":"ENDRA Life Sciences Inc.","ticker":"NDRA","form_type":"8-K","filed_at":"2025-10-15T23:59:59+00:00","items":["1.01","1.02","3.02","5.08","7.01","8.01","9.01"],"status":"ready","headline":"ENDRA raises $4.9M in private placement to launch digital asset treasury strategy managed by Arca","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$4.9M from sale of 744,340 shares/prefunded warrants and warrants at $6.57 per unit; potential $14.4M if all warrants exercised.","Majority of net proceeds to establish a digital asset treasury (DAT) investing in decentralized finance, starting with HYPE; managed by Arca Investment Management.","Up to $1M of proceeds allocated for TAEUS pilot validation imaging study for MASLD/MASH; balance for working capital.","Jeff Dorman, Arca's CIO, appointed to Digital Asset Advisory Board; ATM agreement with Ascendiant terminated.","2025 annual meeting set for Dec 9, 2025; record date Oct 16, 2025; stockholder proposal deadline Oct 27, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":7112431.492537313,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123528,"accession_number":"0001654954-25-011825","cik":1681682,"company_name":"ENDRA Life Sciences Inc.","ticker":"NDRA","form_type":"8-K/A","filed_at":"2025-10-15T23:59:59+00:00","items":["1.01","1.02","3.02","5.08","7.01","8.01","9.01"],"status":"ready","headline":"ENDRA raises $4.9M in private placement to launch digital asset treasury strategy","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 744,340 shares/pre-funded warrants plus up to 1,488,680 common warrants at $6.57 per unit; $6.81 for director participant.","Gross proceeds ~$4.9M; up to $14.4M if common warrants exercised; majority allocated to digital asset treasury (DAT) strategy.","Engaged Arca Investment Management to manage $3.5M of DAT assets; fees 1.25–1.75% AUM + 10–15% performance fee; issued 400,000 advisory warrants.","Terminated at-the-market equity facility with Ascendiant effective October 13, 2025.","2025 annual meeting set for December 9, 2025; record date October 16, 2025; stockholder proposal deadline October 27, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7112431.492537313,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140207,"accession_number":"0001654954-25-008318","cik":1681682,"company_name":"ENDRA Life Sciences Inc.","ticker":"NDRA","form_type":"8-K","filed_at":"2025-07-23T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"ENDRA Life Sciences adopts cryptocurrency treasury strategy, forms advisory board","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Retained Anchorage Digital Bank as custodian; engaged Arca Investment Management to manage crypto holdings and implement bitcoin income strategy.","Formed Cryptocurrency Advisory Board with James Altucher, James Manning (Mawson Infrastructure), and Rayne Steinberg (Arca).","Board authorized development of crypto treasury strategy on July 23, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":7112431.492537313,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140206,"accession_number":"0001654954-25-007893","cik":1681682,"company_name":"ENDRA Life Sciences Inc.","ticker":"NDRA","form_type":"8-K","filed_at":"2025-07-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ENDRA Life Sciences reports Q2 preliminary: no revenue, operating loss $1.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["No revenue for quarter ended June 30, 2025; same as Q2 2024 with zero revenue.","Expected operating loss of ~$1.3M, improved from ~$2.2M loss in Q2 2024.","As of June 30, 2025: cash and equivalents $1.8M; total assets $2.6M; working capital $1.2M.","Firm filed S-1 registration statement to offer shares and warrants in a public offering."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":7112431.492537313,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157854,"accession_number":"0001654954-25-006811","cik":1681682,"company_name":"ENDRA Life Sciences Inc.","ticker":"NDRA","form_type":"8-K","filed_at":"2025-06-11T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"ENDRA posts updated investor presentation reflecting new business strategy announced March 31, 2025","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filed under Item 7.01; presentation posted on company website without new financial or operational data.","No new material facts disclosed; presentation references previously announced strategy shift.","Filing contains only procedural language; investor gains no actionable information from this 8-K alone."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":7112431.492537313,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157853,"accession_number":"0001654954-25-006282","cik":1681682,"company_name":"ENDRA Life Sciences Inc.","ticker":"NDRA","form_type":"8-K","filed_at":"2025-05-30T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"ENDRA Life Sciences receives Nasdaq delisting notice for insufficient stockholders' equity","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Stockholders' equity of $1,752,885 as of March 31, 2025, below Nasdaq's $2.5M minimum.","Nasdaq letter received May 27, 2025; company has until July 11, 2025 to submit a compliance plan.","If plan accepted, company has until November 23, 2025 to regain compliance.","Failure could lead to delisting; company intends to take measures to regain compliance, but no assurance given."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":7112431.492537313,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157852,"accession_number":"0001654954-25-005768","cik":1681682,"company_name":"ENDRA Life Sciences Inc.","ticker":"NDRA","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ENDRA Life Sciences Q1 net loss $1.0M; pivots to metabolic disease diagnostics, plans FDA de novo trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $1.0M in Q1 2025 vs $2.8M in Q1 2024; operating expenses down 46% to $1.5M.","Cash burn improved to $1.2M in Q1 2025 from $1.7M in Q1 2024; cash at April 30 was $2.5M after $0.8M ATM raise.","Strategic pivot to point-of-care liver fat diagnostics for metabolic disease; redesigned TAEUS system with AI.","Revised FDA regulatory strategy: plans prospective multicenter trial of ~250 subjects for De Novo submission.","Two new patents issued in China, bringing IP portfolio to 84 total."],"consensus_eps_estimate":-1.2546,"consensus_eps_actual":-1.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7112431.492537313,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176234,"accession_number":"0001654954-25-003611","cik":1681682,"company_name":"ENDRA Life Sciences Inc.","ticker":"NDRA","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ENDRA Life Sciences Q4 net loss $4.2M, cash burn cut, pivots to GLP-1 metabolic health","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q4 2024 net loss $4.2M ($1.5M in Q4 2023) includes $2.3M non-cash inventory charge; full-year net loss $11.5M.","Cash used in operations Q4 2024 $1.5M, down 32% YoY; expects ~$0.35M/month burn in Q2/Q3 2025.","Cash and equivalents $3.2M at Dec 31, 2024; prior to pivot, runway limited given burn rate.","New strategic direction: TAEUS as biomarker for monitoring GLP-1 drug patients, targeting pharma, concierge, primary care.","Planned De Novo pivotal trial: multi-center, ~250 subjects, hypothesis-driven, with FDA pre-submission alignment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":7112431.492537313,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193125,"accession_number":"0001654954-24-014793","cik":1681682,"company_name":"ENDRA Life Sciences Inc.","ticker":"NDRA","form_type":"8-K","filed_at":"2024-11-22T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"ENDRA Life Sciences regains Nasdaq minimum bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq confirmation on Nov 21, 2024 that it meets Listing Rule 5550(a)(2).","Avoids imminent delisting from Nasdaq; common stock (NDRA) continues trading.","Acting CEO Alex Tokman says company will now focus on new transformational strategies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7112431.492537313,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193124,"accession_number":"0001654954-24-014547","cik":1681682,"company_name":"ENDRA Life Sciences Inc.","ticker":"NDRA","form_type":"8-K","filed_at":"2024-11-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ENDRA Life Sciences Q3 net loss $2.4M, operating expenses down 52% YoY, cash $4.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $2.4M narrowed from $3.1M in Q3 2023; no revenue reported (pre-revenue stage).","Operating expenses fell 52% to $1.5M on $3.1M in annualized cost savings from restructuring.","Cash and cash equivalents were $4.7M as of September 30, 2024.","Accelerated enrollment in global pilot study for TAEUS liver fat assessment; activated site at LMU Germany.","Added AI/ML/DL features to TAEUS; IP portfolio expanded to 82 issued patents."],"consensus_eps_estimate":-1.989,"consensus_eps_actual":-82.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7112431.492537313,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193123,"accession_number":"0001654954-24-013720","cik":1681682,"company_name":"ENDRA Life Sciences Inc.","ticker":"NDRA","form_type":"8-K","filed_at":"2024-11-05T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"ENDRA Life Sciences announces 1-for-35 reverse stock split effective Nov 7, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved a ratio of 1/35 for the reverse stock split authorized by stockholders on Oct 28, 2024.","Amendment to Certificate of Incorporation filed with Delaware Secretary of State on Nov 4, 2024, effective 12:01 a.m. ET on Nov 7, 2024.","Common stock will trade on split-adjusted basis under new CUSIP 29273B 500 beginning Nov 7, 2024.","Each issued share of common stock will be reclassified and converted into 1/35 of a share.","No change to the par value of $0.0001 per share or the authorized number of shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7112431.492537313,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193122,"accession_number":"0001654954-24-013446","cik":1681682,"company_name":"ENDRA Life Sciences Inc.","ticker":"NDRA","form_type":"8-K","filed_at":"2024-10-29T23:59:59+00:00","items":["5.07","8.01"],"status":"ready","headline":"ENDRA Life Sciences stockholders approve reverse stock split; board sets ratio at 1-for-35","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved reverse stock split at Special Meeting on Oct 28, 2024 with 4,241,540 for, 2,792,189 against, 18,228 abstain.","Board of Directors subsequently approved a ratio of 1-for-35 for the reverse stock split.","Reverse split ratio may be implemented at board's discretion within one year of meeting date; all other proposed ratios abandoned."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7112431.492537313,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209508,"accession_number":"0001654954-24-011213","cik":1681682,"company_name":"ENDRA Life Sciences Inc.","ticker":"NDRA","form_type":"8-K","filed_at":"2024-08-28T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"ENDRA Life Sciences gets Nasdaq extension to Nov 20, 2024 to regain $1 bid price; 91% of Series B warrants exercised","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq Hearings Panel granted extension until November 20, 2024 to regain compliance with $1.00 minimum bid price for 10 consecutive trading days.","Company is evaluating options to evidence compliance; no immediate effect on listing or trading of NDRA common stock.","91% of Series B warrants from June 2024 public offering exercised, resulting in issuance of 15,831,864 shares of common stock.","Total outstanding common shares increased to 17,280,655 as of August 28, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7112431.492537313,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209507,"accession_number":"0001654954-24-011072","cik":1681682,"company_name":"ENDRA Life Sciences Inc.","ticker":"NDRA","form_type":"8-K","filed_at":"2024-08-23T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ENDRA Life Sciences appoints new CEO, raises $8M, reduces annual OpEx by $3.1M","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["New acting CEO Alexander Tokman appointed; CFO Richard Jacroux and Regulatory head Ziad Rouag join.","Gross proceeds of $8.0M from public offering of common stock and warrants.","Annualized operating expenses reduced by $3.1M (26%) vs prior year; Q2 OpEx $2.2M.","Cash and cash equivalents $6.4M at June 30, 2024.","Advanced FDA regulatory process; initiated new pilot trials at two North American sites."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7112431.492537313,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209506,"accession_number":"0001654954-24-010837","cik":1681682,"company_name":"ENDRA Life Sciences Inc.","ticker":"NDRA","form_type":"8-K","filed_at":"2024-08-16T23:59:59+00:00","items":["3.03","5.03","7.01","9.01"],"status":"ready","headline":"ENDRA Life Sciences announces 1-for-50 reverse stock split to regain Nasdaq bid price compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split effective Aug 20, 2024; shares outstanding drop from ~72.4M to ~1.4M.","Authorized shares reduced from 1B to 20M; fractional shares are rounded up to whole shares.","Split intended to raise bid price above $1.00 to meet Nasdaq continued listing requirement.","New CUSIP 29273B 401; common stock continues trading under NDRA on Nasdaq.","Board set ratio on Aug 8 after stockholder authorization at Aug 6 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7112431.492537313,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209505,"accession_number":"0001654954-24-010399","cik":1681682,"company_name":"ENDRA Life Sciences Inc.","ticker":"NDRA","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"ENDRA CEO Michelon resigns; board member Tokman named acting CEO, new CFO and regulatory head appointed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Francois Michelon stepped down as CEO and board member effective Aug 12, 2024; separation includes 4 months' salary and 12 months' healthcare coverage.","Alexander Tokman, board member since 2008, appointed acting CEO and Chairman effective Aug 13, 2024; Tokman has 24+ years of commercial leadership and prior GE Healthcare executive experience.","Ziad Rouag appointed Head of Regulatory and Clinical Affairs; Richard Jacroux appointed CFO; Irina Pestrikova to transition and remain advisor.","Tokman will focus on regulatory approval and commercial launch of TAEUS system with strict fiscal discipline.","No disagreement involved in Michelon's resignation; separation agreement includes release of claims and termination of restrictive covenants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":7112431.492537313,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209504,"accession_number":"0001654954-24-010213","cik":1681682,"company_name":"ENDRA Life Sciences Inc.","ticker":"NDRA","form_type":"8-K","filed_at":"2024-08-09T23:59:59+00:00","items":["5.02","5.03","5.07","8.01","9.01"],"status":"ready","headline":"ENDRA Life Sciences approves 1:50 reverse stock split, increases authorized shares to 1B, appoints new Head of Finance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Senior Director of Finance Irina Pestrikova resigned Aug 7; Richard Jacroux appointed Head of Finance & principal financial officer on Aug 8.","Stockholders approved increase in authorized common shares from 80M to 1B; amendment filed Aug 8.","Board set reverse stock split ratio at 1-for-50, authorized by stockholders (range 1:20 to 1:50).","At Aug 6 annual meeting: all five director nominees elected; say-on-pay, warrant issuance, and auditor ratification passed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7112431.492537313,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209503,"accession_number":"0001654954-24-009066","cik":1681682,"company_name":"ENDRA Life Sciences Inc.","ticker":"NDRA","form_type":"8-K","filed_at":"2024-07-17T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Nasdaq notifies ENDRA Life Sciences of delisting due to bid price; company to appeal","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Stock closed below $0.10 for 10 consecutive trading days ended July 12, triggering delisting under Nasdaq Rule 5810(c)(3)(A)(iii).","Company requested hearing on July 16; hearing request automatically stays delisting pending panel decision.","At August 6 annual meeting, company will seek stockholder approval for reverse stock split at ratio between 1:20 and 1:50.","No assurance that Nasdaq panel will grant compliance period or that company will ultimately regain listing compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7112431.492537313,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227578,"accession_number":"0001654954-24-007415","cik":1681682,"company_name":"ENDRA Life Sciences Inc.","ticker":"NDRA","form_type":"8-K","filed_at":"2024-06-06T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"ENDRA Life Sciences prices $8M public offering of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$8M; offering closed June 5, 2024 with Craig-Hallum as placement agent.","61.5M units sold at $0.13 each (or pre-funded at $0.1299), each with Series A and B warrants.","Series A and B warrants exercisable at $0.22; Series B includes alternate cashless exercise at $0.001 for 3 shares.","Warrants require stockholder approval and charter amendment; lock-up of 90 days for company/insiders.","Net proceeds to be used for working capital and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7112431.492537313,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227577,"accession_number":"0001654954-24-006635","cik":1681682,"company_name":"ENDRA Life Sciences Inc.","ticker":"NDRA","form_type":"8-K","filed_at":"2024-05-20T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"ENDRA Life Sciences completes FDA pre-submission meeting for TAEUS liver device","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["In-person FDA pre-sub meeting held May 16, 2024, on TAEUS liver device clinical trial design for de novo submission.","FDA feedback deemed highly constructive; ENDRA to update pivotal study protocol and statistical plan.","Company expects to complete clinical studies by Q4 2024 or Q1 2025, with de novo filing in first half 2025.","Provided background data from 45 historical participants; demonstrated TAEUS procedure with liver phantoms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7112431.492537313,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227576,"accession_number":"0001654954-24-006233","cik":1681682,"company_name":"ENDRA Life Sciences Inc.","ticker":"NDRA","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ENDRA Life Sciences reports Q1 net loss of $2.8M; advances TAEUS liver system with FDA and UK clinical study","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $2.8M ($0.26 per share) vs $2.9M ($0.93 per share) in Q1 2023; operating expenses $2.8M.","Cash and cash equivalents were $1.1M as of March 31, 2024.","First TAEUS system installed at King's College Hospital (UK) for a clinical study evaluating liver fat vs MRI (approx 75 subjects).","FDA pre-submission meeting scheduled in Q2 2024 to align on clinical requirements for De Novo application.","Expanded IP portfolio to 80 issued patents globally; exploring licensing for non-core indications."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":7112431.492537313,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227575,"accession_number":"0001654954-24-005981","cik":1681682,"company_name":"ENDRA Life Sciences Inc.","ticker":"NDRA","form_type":"8-K","filed_at":"2024-05-10T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ENDRA Life Sciences reports expected Q1 2024 net loss of ~$2.8M, zero revenue; files for public offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Expected Q1 2024 net loss of approx. $2.8M vs. $2.9M in Q1 2023; zero revenue in both quarters.","As of March 31, 2024, total assets ~$5.0M, cash ~$1.1M, working capital only ~$54k.","Filed Form S-1/A for public offering of common stock and warrants; terms not disclosed.","Preliminary results are unaudited and subject to final closing and audit adjustments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":7112431.492537313,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227574,"accession_number":"0001654954-24-005552","cik":1681682,"company_name":"ENDRA Life Sciences Inc.","ticker":"NDRA","form_type":"8-K","filed_at":"2024-05-03T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"ENDRA Life Sciences receives Nasdaq bid price deficiency notice; has until Oct 30 to regain compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on May 3, 2024 for closing bid price below $1.00 for 30 consecutive trading days.","Has 180 calendar days, until October 30, 2024, to regain compliance with Minimum Bid Price Requirement.","To cure: bid price must close at or above $1.00 for at least 10 consecutive business days before deadline.","If not cured by Oct 30, may qualify for additional 180-day period if it meets other listing standards.","Company intends to monitor bid price and consider options including a potential reverse stock split."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7112431.492537313,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246392,"accession_number":"0001654954-24-003868","cik":1681682,"company_name":"ENDRA Life Sciences Inc.","ticker":"NDRA","form_type":"8-K","filed_at":"2024-03-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ENDRA Q4 net loss $1.5M, FDA De Novo review ongoing; Q2 meeting set","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 2023: $1.5M ($0.17/share) vs $3.3M ($1.04) in Q4 2022.","Full year 2023 net loss $10.1M ($1.58/share) vs $13.2M ($4.56) in 2022.","Cash and cash equivalents $2.8M as of December 31, 2023.","Installed first TAEUS system at King's College Hospital UK for 75-subject clinical study.","FDA De Novo review ongoing; in-person meeting scheduled for Q2 2024 after Additional Information request."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":7112431.492537313,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}